Multiple Myeloma Research and Treatments

Amyloidosis is characterized by the extracellular deposition of abnormally folded proteins. While localized forms occur in the head and neck, nasopharyngeal involvement is rare and can mimic malignancies.We present a rare case of primary localized nasopharyngeal amyloidosis. A 67-year-old female presented with nasal c…

Background: Elranatamab, a bispecific antibody targeting BCMA and CD3, has demonstrated clinical activity in relapsed/refractory multiple myeloma. Real-world evidence regarding infectious complications and supportive care remains limited. We evaluated the early clinical activity, safety profile, infectious complicatio…

Introduction & Objective: Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), with limited treatment options for steroid-resistant cases. Ruxolitinib, a JAK1/2 inhibitor, has shown promise in treating steroid-resistant acute (aGVHD), chronic (cGVH…

Özet henüz yok.

Objective:Acute myeloid leukemia (AML) is a hematological malignancy characterized by marked clinical and biological heterogeneity, resulting in variable prognosis. Immunophenotypic markers have gained increasing importance in predicting disease outcome and guiding clinical management. This study aimed to evaluate the…

Özet henüz yok.

This study aimed to compare the clinical, demographic, and laboratory characteristics of multiple myeloma patients with spinal involvement who underwent surgical versus non-surgical management.This retrospective, single-center cohort study included 46 multıple myeloma patients with radiologically confirmed spinal invo…

Background and Objectives: The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is an immunonutritional biomarker reflecting systemic inflammation, nutritional status, and immune competence. Its dynamic behavior and prognostic relevance in multiple myeloma (MM) following autologous stem cell transplantation…

Özet henüz yok.

Venetoclax, a selective BCL-2 inhibitor, is widely used in combination with hypomethylating agents as first-line therapy for elderly or unfit patients with AML. Although its safety profile is generally well established, rare immune-mediated adverse events have been scarcely reported. Herein, we present a 62-year-old m…

Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare but devastating complication associated with poor prognosis and limited therapeutic options. We report a 73-year-old woman with high-risk IgG kappa MM harboring TP53 [del(17p)] and 13q deletion who developed extramedullary and CNS disease afte…

7566 Background: B-cell maturation antigen (BCMA)–directed therapies have transformed the treatment landscape in RRMM. Belamaf, a BCMA-targeting antibody-drug conjugate, in combination with Pd significantly improved progression-free survival (PFS) vs PVd (hazard ratio [HR], 0.52; 95% CI, 0.37-0.73; P <0.001) in pts wi…